Drug
IMR-687
IMR-687 is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
1(17%)
Results Posted
150%(3 trials)
Terminated
2(33%)
Phase Distribution
Ph phase_2
5
83%
Ph phase_1
1
17%
Phase Distribution
1
Early Stage
5
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
5(83.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
40.0%
2 of 5 finished
Non-Completion Rate
60.0%
3 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(2)
Terminated(3)
Detailed Status
Terminated2
Completed2
Withdrawn1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (16.7%)
Phase 25 (83.3%)
Trials by Status
terminated233%
withdrawn117%
completed233%
active_not_recruiting117%
Recent Activity
1 active trials
Showing 5 of 6
completedphase_1
A Study of IMR-687 in Healthy Adult Volunteers
NCT02998450
completedphase_2
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
NCT03401112
terminatedphase_2
A Study of IMR-687 in Subjects With Sickle Cell Disease
NCT04474314
withdrawnphase_2
Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
NCT05312021
terminatedphase_2
A Study of IMR-687 in Subjects With Beta Thalassemia
NCT04411082
Clinical Trials (6)
Showing 6 of 6 trials
NCT02998450Phase 1
A Study of IMR-687 in Healthy Adult Volunteers
NCT03401112Phase 2
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
NCT04474314Phase 2
A Study of IMR-687 in Subjects With Sickle Cell Disease
NCT05312021Phase 2
Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
NCT04411082Phase 2
A Study of IMR-687 in Subjects With Beta Thalassemia
NCT04053803Phase 2
An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6